Prognostic value of Ezrin in solid tumors: a meta-analysis of the literature.
Prognostic value of Ezrin in solid tumors: a meta-analysis of the literature.
复制标题
Ezrin 在实体瘤中的预后价值：文献荟萃分析
DOI：
10.1371/journal.pone.0068527
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Min D
中科院分区：
文献类型：
--
作者：
Han K;Qi W;Gan Z;Shen Z;Yao Y;Min D
目的Ezrin是一种参与肿瘤生长和侵袭的细胞骨架蛋白。然而，其对实体瘤患者生存的预后价值仍存在争议。方法计算机检索Pubmed、Embase和科克伦数据库。终点为总生存期（OS）、无进展生存期（PFS）。根据纳入试验的异质性，采用固定或随机效应模型计算汇总风险比（HR）或比值比（OR）和95%置信区间（CI）。结果最终确定了27个合格的试验，涉及4693例患者。计算所有研究的汇总风险比（HR）和亚组风险比。联合HR表明，在所有合格的研究中，阳性Ezrin表达对总生存期（OS）[1.95，95%置信区间（CI）1.60-2.39; P<0.001]和无进展生存期（PFS）有影响：（2.30，95% CI 1.0-3.61; P = 0.001）。 根据肿瘤类型、地区、患者数量和发表年份进行亚组分析也观察到类似结果。结论Ezrin蛋白的表达可能是实体瘤患者预后不良的一个因素。因此，现在需要大型设计良好的前瞻性研究来证实Ezrin作为独立预后标志物的临床效用。
Purpose Ezrin is a cytoskeletal protein involved in tumor growth and invasion. However its prognostic value for survival in patients with solid tumor remains controversial. Methods Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials. Results Twenty-seven eligible trials involving 4693 patients were ultimately identified. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive Ezrin expression had an impact on overall survival (OS) [1.95, 95% confidence interval (CI) 1.60–2.39; P<0.001] in all eligible studies and progress free survival (PFS): (2.30 95% CI 1.0–3.61; P = 0.001). Similar results were also observed in subgroup analysis, according to tumor types, regions, patients' number and publication year. Conclusions Our findings suggested that Ezrin protein expression might be a factor for a poor prognosis in patients with solid tumor. So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.
登录
查看更多内容
影响因子：
15.8
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
DOI：
10.1186/bcr1006
发表时间：
2005
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Elliott BE;Meens JA;SenGupta SK;Louvard D;Arpin M
通讯作者：
Arpin M
影响因子：
2.8
作者：
Li, Li;Wang, Yuan-Yu;Ma, Jie
通讯作者：
Ma, Jie
影响因子：
3.4
作者：
Carneiro, Ana;Bendahl, Par-Ola;Nilbert, Mef
通讯作者：
Nilbert, Mef
影响因子：
6.1
作者：
Ma Li;Liu Yue-ping;Li Zeng-huai
通讯作者：
Li Zeng-huai